Popular terms

[SEARCH]

Factor Viii topics
Factor Viii
Nucleotide
Antibodies
Polynucleotide
Polypeptide
Sialic Acid
Circulatory
Recombinant
Ethylene Glycol
Coagulation
Hemophilia
Physiologic
Endogenous
Prophylaxis
Blood Coagulation

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Factor Viii patents



      
           
This page is updated frequently with new Factor Viii-related patent applications. Subscribe to the Factor Viii RSS feed to automatically get the update: related Factor RSS feeds. RSS updates for this page: Factor Viii RSS RSS



Date/App# patent app List of recent Factor Viii-related patents
07/30/15
20150210737 
 Integrated process for the production of therapeutics (human albumin, intravenous immunoglobulins, clotting factor viii and clotting factor ix) from human plasma patent thumbnailnew patent Integrated process for the production of therapeutics (human albumin, intravenous immunoglobulins, clotting factor viii and clotting factor ix) from human plasma
The purification carried out by an all-chromatography scheme, avoids the use of ethanol precipitation in the entire manufacturing process of the said four plasma products. The invention describes an integrated process for purifying four different proteins from human plasma to high therapeutic grade purity levels, with a potential to purify more therapeutic proteins from a given plasma sample by incorporating additional chromatography steps in the sequence..

07/16/15
20150197552 
 Compositions and methods of treatment of black hemophiliac patients patent thumbnailCompositions and methods of treatment of black hemophiliac patients
It has been determined that most mutations in factor viii occur in multiple haplotypes, not primarily in one haplotype. The frequencies of mild, moderate, and severe hemophilia did not differ significantly according to the background haplotype.
Haplomics, Inc.


07/16/15
20150196017 
 Compositions and methods of treatment of black hemophiliac patients patent thumbnailCompositions and methods of treatment of black hemophiliac patients
It has been determined that most mutations in factor viii occur in multiple haplotypes, not primarily in one haplotype. The frequencies of mild, moderate, and severe hemophilia did not differ significantly according to the background haplotype.
Haplomics, Inc.


07/09/15
20150191526 
 Cell line expressing single chain factor viii polypeptides and uses thereof patent thumbnailCell line expressing single chain factor viii polypeptides and uses thereof
The present invention provides cell lines for producing single chain fviii polypeptides, e.g., chimeric single chain fviii polypeptides, methods of producing single chain fviii polypeptides, single chain fviii polypeptides, and methods of treating hemophilia a with a single chain factor viii polypeptide.. .
Biogen Idec Ma Inc.


07/09/15
20150190478 
 New protecting compositions for recombinantly produced factor vii patent thumbnailNew protecting compositions for recombinantly produced factor vii
A histidine-free composition comprising: a high purity factor viii (r-factor viii); arginine and/or sucrose; a surface-active agent to prevent or at least inhibit surface adsorption of factor viii; an amount of calcium chloride for specific stabilization of factor viii.. .
Octapharma Ag


06/11/15
20150158930 
 Factor viii sequences patent thumbnailFactor viii sequences
There is provided a nucleic acid molecule comprising a nucleotide sequence encoding for a functional factor viii protein, wherein the portion of the nucleotide sequence encoding for the b domain of the factor viii protein is between 90 and 111 nucleotides in length and encodes for an amino acid sequence comprising a sequence having at least 85% identity to seq id no: 4 and which comprises six asparagine residues. Also provided is a functional factor viii protein, a vector comprising the above nucleic acid molecule, a host cell, a transgenic animal, a method of treating haemophilia, e.g.
St. Jude Children's Research Hospital


06/11/15
20150158929 
 Factor viii compositions and methods of making and using same patent thumbnailFactor viii compositions and methods of making and using same
The present invention relates to compositions comprising factor viii coagulation factors linked to extended recombinant polypeptide (xten), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor viii-related diseases, disorders, and conditions.. .
Biogen Idec Ma Inc.


06/11/15
20150158906 
 Method of purifying therapeutic proteins patent thumbnailMethod of purifying therapeutic proteins
Also provided are solutions and pharmaceutical formulations comprising the fibrinogen and/or factor viii and/or vwf recovered by such methods, and uses thereof.. .

03/26/15
20150087593 
 Coagulation factor viii with reduced immunogenicity patent thumbnailCoagulation factor viii with reduced immunogenicity
B. Modification of said epitope(s) by eliminating at least one hydrophobic aminoacid residues in position p1 and/or p7, substituting at least one hydrophobic aminoacid residue in position p1 and/or p7 with a non-hydrophobic residue, or adding a non-hydrophobic residue in position p1 and/or p7..

03/19/15
20150080304 
 Treatment and prevention of radiation injury using mfg-e8 patent thumbnailTreatment and prevention of radiation injury using mfg-e8
Methods and compositions are disclosed for treating and preventing radiation injury using milk fat globule epidermal growth factor-factor viii (mfg-e8).. .
The Feinstein Institute For Medical Research


03/19/15
20150079072 

Assays to monitor bleeding disorders


The present invention provides methods of dosing factor viii or factor ix chimeric and hybrid polypeptides. The present invention further provides high-sensitivity methods of quantifying an amount of activated fix protein in a test sample.
Biogen Idec Hemophilia Inc.


03/12/15
20150071883 

Adeno-associated virus factor viii vectors


The invention provides improved adeno-associated virus (aav) factor viii (fviii) vectors, including aav fviii vectors that produce a functional factor viii polypeptide and aav fviii vectors with high expression activity.. .
Biomarin Pharmaceutical Inc.


02/26/15
20150056271 

Compositions and methods for enhancing coagulation factor viii function


factor viii variants and methods of use thereof are disclosed.. .
The Children's Hospital Of Philadelphia


02/05/15
20150038422 

Unit dosage forms of pharmaceutical compositions comprising a polymer-factor viii polypeptide conjugate


Conjugates of a factor viii moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof.
Nektar Therapeutics


02/05/15
20150038421 

Factor viii compositions and methods of making and using same


The present invention relates to compositions comprising factor viii coagulation factors linked to extended recombinant polypeptide (xten), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor viii-related diseases, disorders, and conditions.. .
Amunix Operating Inc.


02/05/15
20150037301 

Recombinant factor viii having enhanced stability following mutation at the a1-c2 domain interface


The invention relates to a recombinant factor viii that includes one or more mutations at an interface of a1 and c2 domains of recombinant factor viii. The one or more mutations include substitution of one or more amino acid residues with either a cysteine or an amino acid residue having a higher hydrophobicity.
University Of Rochester


01/22/15
20150025010 

Novel albumin-free factor viii formulations


A factor viii composition formulated without albumin, comprising the following formulation excipients in addition to factor viii: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mm to 5 mm calcium salt; 100 mm to 300 mm nacl; and a buffering agent for maintaining a ph of approximately between 6 and 8. Alternatively, the formulation can comprise 2% to 6% hydroxyethyl starch; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mm to 5 mm calcium salt; 100 mm to 300 mm nacl; and a buffering agent for maintaining a ph of approximately between 6 and 8.
University Of Connecticut


01/22/15
20150023959 

Chimeric factor viii polypeptides and uses thereof


The present invention provides a vwf fragment comprising the d′ domain and d3 domain of vwf, a chimeric protein comprising the vwf fragment and a heterologous moiety, or a chimeric protein comprising the vwf fragment and a fviii protein and methods of using the same. A polypeptide chain comprising a vwf fragment of the invention binds to or is associated with a polypeptide chain comprising a fviii protein and the polypeptide chain comprising the vwf fragment can prevent or inhibit binding of endogenous vwf to the fviii protein.
Biogen Idec Ma Inc.


01/22/15
20150023946 

Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor viii


The present invention relates to pharmaceutical preparations comprising factor viii, a sulfated glycosaminoglycan and a hyaluronidase for the non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders. The invention further relates to the combined use of a factor viii, a sulfated glycosaminoglycan and a hyaluronidase for the treatment and prevention of bleeding disorders, and to a method for increasing the bioavailability after non-intravenous administration of factor viii by co-adminstration of a sulfated glycosaminoglycan and a hyaluronidase..
Csl Behring Gmbh


01/01/15
20150005473 

Recombinant expression vector system for variants of coagulation factor viii and von willebrand factor


Disclosed is an expression vector system for variants of coagulation factor viii (fviii) and von willebrand factor (vwf). In detail, mutant vwf the size of which is significantly reduced by deleting exons but which has remarkably increased fviii stabilizing and activating efficiency, and an expression vector system useful for the treatment of hemophilia which is capable of expressing the same along with fviii are disclosed.
Korea University Industrial & Academic Collaborative Foundation


01/01/15
20150004218 

Compositions and methods for immune tolerance induction


Methods and compositions to reduce immunogenicity of proteins are disclosed. Compositions comprising therapeutic proteins (such as factor viii or any other protein or peptide) complexed with liposomes comprising ps and pc (ps liposomes), or comprising ps, pi and pc and, optionally, cholesterol (ps/pi liposomes) may be used..
The Research Foundation For The State University Of New York


12/18/14
20140370035 

Methods of reducing immunogenicity against factor viii in individuals undergoing factor viii therapy


The present disclosure provides methods of administering chimeric and hybrid factor viii (fviii) polypeptides comprising fviii and fc to subjects at risk of developing inhibitory fviii immune responses, including anti-fviii antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to fviii.
Puget Sound Blood Center


12/18/14
20140370018 

Multi-specific antigen-binding molecules and uses thereof


Various bispecific antibodies that specifically bind to both blood coagulation factor ix/activated blood coagulation factor ix and blood coagulation factor x and functionally substitute for the cofactor function of blood coagulation factor viii, that is, the function to promote activation of blood coagulation factor x by activated blood coagulation factor ix, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor viii were successfully discovered..
Chugai Seiyaku Kabushiki Kaisha


12/04/14
20140357565 

Method of producing factor viii proteins by recombinant methods


Provided herein are methods and compositions for producing factor viii proteins. Such methods include introducing into a cell a nucleic acid molecule encoding a factor viii protein operably linked to a promoter, wherein the promoter is characterized by the ability to produce commercially viable factor viii protein; and incubating the cell under conditions for producing commercially viable factor viii protein.

12/04/14
20140357564 

Von willebrand factor variants having improved factor viii binding affinity


The present invention relates to a polypeptide comprising a modified von willebrand factor (vwf) having a higher factor viii binding affinity than non-modified vwf, its pharmaceutical use and method of its preparation.. .

11/20/14
20140342979 

Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients


The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, victoza (liraglutide), tresiba (insulin degludec), ryzodeg (insulin degludec/insulin aspart), ideglira (liraglutide and insulin degludec), novoseven (recombinant human coagulation factor viia), novoseven rt (recombinant human coagulation factor viia), or turoctocog alfa (third-generation recombinant coagulation factor viii)..

10/23/14
20140315815 

Use of sulfated glycosaminoglycans for improving the bioavailability of factor viii


The present invention relates to pharmaceutical preparations comprising one or more factor viii and a sulfated glycosaminoglycan for increasing the bioavailability of factor viii upon non-intravenous administration. The invention further relates to the combined use of factor viii and a sulfated glycosaminoglycan for the treatment and prevention of bleeding disorders, whereby the bioavailability of factor viii is increased, and to a method for increasing the bioavailability after non-intravenous administration of factor viii by coadminstration of a sulfated glycosaminoglycan..

10/16/14
20140308707 

Method for production of factor viii


The present invention relates to methods of producing a factor viii polypeptide in mammalian cell cultures.. .

10/16/14
20140308280 

Factor viii polypeptide formulations


The present invention provides a formulation of a factor viii polypeptide, e.g., fviii-fc, and methods of using the same. The fviii polypeptide can be a recombinant fviii protein, a short-acting fviii protein, or a long-acting fviii protein.

10/02/14
20140294821 

Factor viii chimeric and hybrid polypeptides, and methods of use thereof


The present invention provides methods of administering factor viii (processed fviii, single chain fviii, or a combination thereof); methods of administering chimeric and hybrid polypeptides comprising factor viii; chimeric and hybrid polypeptides comprising factor viii; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells. .

09/18/14
20140273096 

Modified coagulation factors with prolonged in vivo half-life


The present invention relates to nucleic acid sequences coding for modified coagulation factors, preferably coagulation factor viii, and their derivatives; recombinant expression vectors containing such nucleic acid sequences; host cells transformed with such recombinant expression vectors; and recombinant polypeptides and derivatives coded for by said nucleic acid sequences, whereby said recombinant polypeptides and derivatives have biological activities and prolonged in vivo half-lives compared to the unmodified wild-type proteins. The invention also relates to corresponding sequences that result in improved in vitro stability.

09/18/14
20140271625 

Methods for treating bleeding disorders


Disclosed are methods for treating bleeding disorders, such as hemophilia, in subjects in need thereof by administering an antibody that specifically binds cd73. The methods reduce production of adenosine, increase platelet activation and/or enhance the level of coagulation on the platelet surface to reduce and/or stop bleeding.

09/18/14
20140271606 

Methods of using adenosine receptor antagonists for treating bleeding disorders


Methods of treating bleeding disorders, such as bleeding diseases such as hemophilia, by administering adenosine 2a receptor and/or adenosine 2b receptor antagonists to subjects in need thereof are disclosed. In some embodiments, the methods further include administration of the antagonist with one or more of factor viii, factor ix and factor xi to treat the bleeding disorder..

09/04/14
20140249086 

Method for improving the stability of purified factor viii after reconstitution


The present invention relates to a method for increasing the stability of a factor viii molecule after purification, lyophilization and reconstitution, comprising preventing proteolytic cleavage of the factor viii molecule into a first fragment comprising essentially the a1 domain and the a2 domain and a second fragment comprising essentially the a3 domain, the c1 domain and the c2 domain throughout manufacturing of the factor viii molecule. The invention further pertains to a method for improving the bioavailability of factor viii after intravenous and non-intravenous injection..

08/28/14
20140242057 

Conjugated factor viii molecules


The present invention relates to b-domain truncated factor viii molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules..

08/21/14
20140232029 

Kit for measuring the thrombin generation in a sample of a patient's blood or plasma


The invention provides a kit for measuring the thrombin generation in a sample of a patient's blood or plasma, or in a sample of clotting factors. The kit contains lyophilized tissue factor/phospholipid-complex and a lyophilized mixture containing a thrombin-substrate and cacl2.

08/07/14
20140221611 

Binding molecules for human factor viii and factor viii-like proteins


It is an object of the present invention to provide novel binding molecules for factor viii and factor viii-like proteins. Preferred binding molecules of the present invention exhibit not only distinct characteristics for binding of the target factor viii polypeptides but also specific and desirable characteristics for release (elution) of the target polypeptides.

07/10/14
20140193880 

Modified factor viii and factor ix genes and vectors for gene therapy


The present invention relates to a modified and optimized factor viii or factor ix nucleic acid for inclusion in a chimeric virus vector. Use of such vector can be used for treatment of hemophilia..

07/10/14
20140193441 

Method of administering porcine b-domainless fviii


The present invention provides a method of administering porcine b-domainless factor viii (obi-1) to a patient having factor viii deficiency to provide more rapid and effective protection against bleeding episodes, compared to formerly available methods, or to provide more effective protection to such patients during non-bleeding periods. This invention is based on the discovery that the recombinant b-domainless porcine fviii, termed obi-1, has greater bioavailability compared to the natural porcine fviii partially purified from porcine plasma, termed hyate:c.

06/05/14
20140154233 

Method of purifying therapeutic proteins


The present invention relates generally to a method of reducing the level of plasminogen and/or tissue plasminogen activator and/or other protease(s) in a solution comprising fibrinogen and/or factor viii and/or von willebrand factor (vwf), the method comprising: (i) passing a feedstock comprising fibrinogen and/or factor viii and/or vwf through a hydrophobic charge-induction chromatographic resin under conditions selected such that the plasminogen and/or tissue plasminogen activator and/or other protease(s) is bound to the resin; and (ii) recovering the solution comprising fibrinogen and/or factor viii and/or vwf which passes through the resin; wherein the concentration of the plasminogen and/or tissue plasminogen activator and/or protease(s) in the recovered solution is reduced by at least 50% compared to the feedstock. Also provided are solutions and pharmaceutical formulations comprising the fibrinogen and/or factor viii and/or vwf recovered by such methods, and uses thereof..

05/22/14
20140140987 

Manufacturing and purification processes of complex protein found in fraction iv to make a separated apo, transferrin, and alpha 1 anti strepsin (a1at) or a combined transferrin/apo/human albumin/a1at and all new found proteins


A method of introducing healthy good human cells to eat up bad damaged cells, comprising administering an effective amount of a healthy good protein containing transferrin, alpha 1-antitrypsin, apolipoprotein a and human albumin. The method further comprises administering an effective amount of a protein containing apoa1/2/4, or administering an effective amount of a protein containing factor ii, factor vii, factor ix and factor x in prothrombin complex concentrate.

05/08/14
20140128325 

Von willebrand factor or factor viii and von willebrand factor for the treatment of coagulopathy induced by inhibitors of thrombocytes


The present invention relates to a von willebrand factor for use in the treatment and/or prevention of a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes. Furthermore, the present invention relates to a method of treating and/or preventing a disorder related to a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes comprising administering a pharmaceutically effective amount of a von-willebrand-factor (vwf) to a patient in need thereof.

05/01/14
20140121163 

Mfg-e8 and uses thereof


Methods of treating cerebral ischemia using milk fat globule epidermal growth factor-factor viii (mfg-e8) are disclosed, as are recombinant human mfg-e8 and its uses in pharmaceutical compositions, products and methods for treating inflammation and organ injury after ischemia/reperfusion, sepsis, and lung injury.. .

05/01/14
20140120071 

Recombinant factor viii having enhanced stability following mutation at the a1-c2 domain interface


The invention relates to a recombinant factor viii that includes one or more mutations at an interface of a1 and c2 domains of recombinant factor viii. The one or more mutations include substitution of one or more amino acid residues with either a cysteine or an amino acid residue having a higher hydrophobicity.

03/13/14
20140072561 

Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life


The present invention relates to modified nucleic acid sequences coding for coagulation factor viii (fviii) and for von willebrand factor (vwf) as well as complexes thereof and their derivatives, recombinant expression vectors containing such nucleic acid sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives coded for by said nucleic acid sequences which recombinant polypeptides and derivatives do have biological activities together with prolonged in vivo half-life and/or improved in vivo recovery compared to the unmodified wild-type protein. The invention also relates to corresponding fviii sequences that result in improved expression yield.

02/27/14
20140057848 

Factor viii variants having a decreased cellular uptake


The present invention relates to modified coagulation factors. In particular, the present invention relates to modified factor viii molecules having decreased cellular uptake..

02/27/14
20140056861 

Recombinant factor viii having increased stability


The present invention relates to a recombinant factor viii that includes one or more mutations that result in enhanced stability of both factor viii and factor viiia. Methods of making and using the recombinant factor viii, and pharmaceutical compositions containing the same are also disclosed.

02/20/14
20140051832 

Method for the production of recombinant human factor viii


The object of the present invention is to provide methods for the production of recombinant human factor viii, employing specific endoproteases, thus assuring full proteolytic processing of said factor even during its biosynthesis, consequently avoiding additional purification steps. Other objects of the present invention are the recombinant human factor viii as obtained by said methods, pharmaceutical compositions, related uses and therapeutic methods..

02/20/14
20140051123 

Method of increasing the productivity of eucaryotic cells in the production of recombinant fviii


A method of increasing productivity, in particularly cell-specific productivity, of recombinant factor viii (rfviii) produced in a eukaryotic cell suspension during culturing of the eucaryotic cell suspension in a culturing medium containing not more than 500 μm cacl2, at least a non-ionic detergent and other nutrient components needed for the cells to grow and produce rfviii, the cell suspension is cultured under conditions inducing a shear stress mechanically to the eucaryotic cell suspension by adding a power density of at least 3 w/m3.. .

02/06/14
20140037632 

Multi-specific antigen-binding molecules and uses thereof


Various bispecific antibodies that specifically bind to both blood coagulation factor ix/activated blood coagulation factor ix and blood coagulation factor x and functionally substitute for the cofactor function of blood coagulation factor viii, that is, the function to promote activation of blood coagulation factor x by activated blood coagulation factor ix, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor viii were successfully discovered..



Popular terms: [SEARCH]

Factor Viii topics: Factor Viii, Nucleotide, Antibodies, Polynucleotide, Polypeptide, Sialic Acid, Circulatory, Recombinant, Ethylene Glycol, Coagulation, Hemophilia, Physiologic, Endogenous, Prophylaxis, Blood Coagulation

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Factor Viii for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Factor Viii with additional patents listed. Browse our RSS directory or Search for other possible listings.


3.6898

4794

3 - 0 - 102